SBIR-STTR Award

Community Oriented Tool for Reducing Melanoma Health Disparities
Award last edited on: 4/11/16

Sponsored Program
SBIR
Awarding Agency
NIH : NIBIB
Total Award Amount
$396,123
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Eric R Craine

Company Information

Western Research Company Inc

3275 West Ina Road Suite 215
Tucson, AZ 85741
   (520) 325-4505
   western@wrc-inc.com
   www.wrc-inc.com
Location: Multiple
Congr. District: 06
County: Pima

Phase I

Contract Number: 1R43EB011984-01A1
Start Date: 8/1/11    Completed: 7/31/13
Phase I year
2011
Phase I Amount
$199,678
Melanoma is a frequently fatal cancer that, if detected early, is relatively easily cured. This disease is rapidly increasing in frequency and has recently been identified by the National Center for Health Statistics Health Disparities Study as a high profile health disparity. Further it has been noted to occur more frequently now in both young people and Hispanic populations. We have developed a unique, proprietary and innovative self-screening imaging technology (DermAlert) that has the potential to significantly mitigate disparate melanoma outcomes by more fully involving people at-risk of melanoma in their own healthcare, and by enabling much earlier detection of new and changed pigmented lesions that may be early melanomas. The goal of this NIH grant program is to address key issues (patient related causes for the disparity and physician/insurance requirements for efficacy demonstration) for the translation of this technology into the at- risk community to realize reduction in melanoma disparity. We propose a program to research the efficacy of DermAlert imaging self screening for new and changed pigmented lesions, and to provide education that will be useful in overcoming barriers to use of the DermAlert system in affected populations. Phase I activities will include: "" Conversion of DermAlert to a Spanish language resource, "" Analysis of specific classes of barriers to use of imaging by groups suffering melanoma health disparities, "" Development of education and outreach tools to help overcome barriers to use of self imaging screening, "" Preliminary evaluation of the effect of DermAlert use on health outcomes, and "" Preparation for an expanded, large scale efficacy study during Phase II. As pigmented lesions, for which change was detected by the imaging system, are biopsied, the results of those biopsies will be tabulated and statistically compared with control set of biopsies for which imaging was not a motivating factor. Using this approach it will be possible to investigate not only patient compliance in the use of the imaging system, but also its utility in helping to guide more effective biopsy decisions. This part of the project will address its efficacy and the resultant medical outcomes Measureable milestones during Phase I include the following, which can be used to help assess the viability of progressing to Phase II research: "" Qualitative and quantitative identification of specific barriers to imaging that contribute to the health disparity "" Preparation of an educational video for helping patients and physicians overcome barriers to use of this technology, and "" Foundation and preliminary analysis of an archive of follow-up biopsy data for evaluation of efficacy of using DermAlert. Successful completion of the project will result in enhanced awareness and reduced barriers to use of a completely unique imaging protocols which will more deeply involve patients in their personal health care, contribute to earlier detection of potential melanomas, and have the power to ultimately reduce the number of unnecessary biopsies and reduce patient mortality at the hands of a serious health disparity.

Public Health Relevance:
Melanoma is a serious, and growing, public health disparity;to help combat it physicians urge people to look for new and changed pigmented moles on their skin. This is presently a very challenging task for people;however, this project will seek to reduce barriers to use of a reliable, at-home digital photography tool to assist people in finding these changes. Wide use of this technology can reduce the health disparities of melanoma.

Thesaurus Terms:
Active Follow-Up;Address;Affect;Archives;Awareness;Biopsy;Cancers;Communities;Compliance Behavior;Data;Data Collection;Development;Digital Photography;Disease;Disorder;Early Diagnosis;Education;Education And Outreach;Educational Aspects;Evaluation;Foundations;Frequencies (Time Pattern);Frequency;Goals;Grant;Hand;Health;Healthcare;Hispanic Populations;Hispanics;Home;Home Environment;Image;Imaging Technology;Instruction And Outreach;Insurance;Loinc Axis 4 System;Language;Latino Population;Lesion;Literature;Malignant Melanoma;Malignant Neoplasms;Malignant Tumor;Manuscripts;Medical;Mole The Mammal;Moles;Mortality;Mortality Vital Statistics;Nchs;Nih;National Center For Health Statistics;National Center For Health Statistics (U.S.);National Institutes Of Health;Outcome;Patient Compliance;Patient Cooperation;Patients;Personal Awareness;Phase;Physicians;Pigments;Population;Preparation;Process;Protocol;Protocols Documentation;Public Health;Qualitative Research;Research;Research Resources;Resources;Risk;Screening Procedure;Self Perception;Self Image;Self View;Skin;Spanish Origin;Staging;System;Technology;Training And Outreach;Translations;Treatment Compliance;Tutoring And Outreach;United States National Center For Health Statistics;United States National Institutes Of Health;Combat;Compliance Cooperation;Developmental;Disease/Disorder;Early Detection;Efficacy Evaluation;Efficacy Research;Follow Up;Follow-Up;Followed Up;Health Care;Health Disparities;Health Disparity;Hispanic Community;Imaging;Improved;Innovate;Innovation;Innovative;Malignancy;Melanoma;Neoplasm/Cancer;Patient Adherence;Programs;Public Health Medicine (Field);Screening;Screenings;Self Awareness;Self Knowledge;Therapy Compliance;Therapy Cooperation;Tool

Phase II

Contract Number: 5R43EB011984-02
Start Date: 8/1/11    Completed: 7/31/13
Phase II year
2012
Phase II Amount
$196,445
Melanoma is a frequently fatal cancer that, if detected early, is relatively easily cured. This disease is rapidly increasing in frequency and has recently been identified by the National Center for Health Statistics Health Disparities Study as a high profile health disparity. Further it has been noted to occur more frequently now in both young people and Hispanic populations. We have developed a unique, proprietary and innovative self-screening imaging technology (DermAlert) that has the potential to significantly mitigate disparate melanoma outcomes by more fully involving people at-risk of melanoma in their own healthcare, and by enabling much earlier detection of new and changed pigmented lesions that may be early melanomas. The goal of this NIH grant program is to address key issues (patient related causes for the disparity and physician/insurance requirements for efficacy demonstration) for the translation of this technology into the at- risk community to realize reduction in melanoma disparity. We propose a program to research the efficacy of DermAlert imaging self screening for new and changed pigmented lesions, and to provide education that will be useful in overcoming barriers to use of the DermAlert system in affected populations. Phase I activities will include: "" Conversion of DermAlert to a Spanish language resource, "" Analysis of specific classes of barriers to use of imaging by groups suffering melanoma health disparities, "" Development of education and outreach tools to help overcome barriers to use of self imaging screening, "" Preliminary evaluation of the effect of DermAlert use on health outcomes, and "" Preparation for an expanded, large scale efficacy study during Phase II. As pigmented lesions, for which change was detected by the imaging system, are biopsied, the results of those biopsies will be tabulated and statistically compared with control set of biopsies for which imaging was not a motivating factor. Using this approach it will be possible to investigate not only patient compliance in the use of the imaging system, but also its utility in helping to guide more effective biopsy decisions. This part of the project will address its efficacy and the resultant medical outcomes Measureable milestones during Phase I include the following, which can be used to help assess the viability of progressing to Phase II research: "" Qualitative and quantitative identification of specific barriers to imaging that contribute to the health disparity "" Preparation of an educational video for helping patients and physicians overcome barriers to use of this technology, and "" Foundation and preliminary analysis of an archive of follow-up biopsy data for evaluation of efficacy of using DermAlert. Successful completion of the project will result in enhanced awareness and reduced barriers to use of a completely unique imaging protocols which will more deeply involve patients in their personal health care, contribute to earlier detection of potential melanomas, and have the power to ultimately reduce the number of unnecessary biopsies and reduce patient mortality at the hands of a serious health disparity.